Ann: Q4 FY2020 Business Update and Appendix 4C, page-4

Highlights:

* Healthy Q4 sales performance despite challenging market, with $3.7M contracted revenue added in the quarter, more than double the corresponding period last year

* Final FY2020 revenue anticipated to be in the range of $18.4M and $18.7M

* $12.8M in revenue has already been contracted to be recognised in FY21 with a further $17.0M sold out to FY2025

* Net operating cash flow surplus for the quarter of $0.25M, resulting in cash reserves of $15.9M at 30 June 2020

* Cash receipts for the quarter from operations of $7.6M, consistent with usual uplift at year-end

* Alcidion products have been enhanced for in-hospital and remote monitoring of COVID-19 patients and deployed live into hospitals

* Significant contracts signed and announced since 1 April 2020 include:

o NHS Fife – 5-year Patientrack extension across entire board
o NHS Lanarkshire – 5-year agreement to implement Patientrack across board

o Sydney LHD – initial 12-month contract for Miya Precision to support COVID-19 virtual care

o Murrumbidgee LHD – 12-month contract for full Miya Precision platform including MEMRe

o ACT Health – 2-year extension to long term integration support contract